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Immune Responses to Vi Capsular Polysaccharide Typhoid Vaccine in
Children 2 to 16 Years Old in Karachi, Pakistan, and Kolkata, India
R. Leon Ochiai,a* M. Imran Khan,a* Sajid B. Sooﬁ,b Dipika Sur,c Suman Kanungo,c Young Ae You,a M. Atif Habib,b
Shah Muhammad Sahito,b* Byomkesh Manna,c Shanta Dutta,c Camilo J. Acosta,a* Mohammad Ali,a* Sujit K. Bhattacharya,c*
Zulﬁqar A. Bhutta,b* John D. Clemensa*
International Vaccine Institute, Seoul, Republic of Koreaa; Department of Paediatrics, Aga Khan University, Karachi, Pakistanb; National Institute of Cholera and Enteric
Diseases, Kolkata, Indiac
The geometric mean concentration (GMC) and the proportionmaintaining a protective level (150 enzyme-linked immunosor-
bent assay (ELISA) units [ELU]/ml) 2 years following a single dose of 25g of injectable Vi capsular polysaccharide typhoid vac-
cine was measured against that of the control hepatitis A vaccine in children 2 to 16 years old in cluster randomized trials in Ka-
rachi and Kolkata. The GMC for the Vi group (1,428 ELU/ml) was statistically significantly different from the GMC of the
control hepatitis A vaccine group (86 ELU/ml) after 6 weeks. A total of 117 children (95.1%) in the Vi group and 9 (7.5%) in the
hepatitis A group showed a 4-fold rise in Vi IgG antibody concentrations at 6 weeks (P< 0.01). Protective antibody levels re-
mained significantly different between the two groups at 2 years (38% in the Vi vaccine groups and 6% in the hepatitis A group
[P< 0.01]). A very small proportion of younger children (2 to 5 years old) maintained protective Vi IgG antibody levels at 2
years, a result that was not statistically significantly different compared to that for the hepatitis A group (38.1% versus 10.5%).
The GMCs of the Vi IgG antibody after 2 years were 133 ELU/ml for children 2 to<5 years old and 349 ELU/ml for children 5 to
16 years old. In conclusion, Vi capsular polysaccharide typhoid vaccine is immunogenic in children in settings of South Asia
where typhoid is highly endemic. The antibody levels in children who received this vaccine remained higher than those in chil-
dren who received the control vaccine but were significantly reduced at 2 years of follow-up.
Typhoid fever is amajor bacterial infection in developing coun-tries (1). Typhoid fever, until recently, was considered a dis-
ease of high incidence in children older than 5 years and endemic
in South and South-East Asia. However, the data gathered in the
past 10 years have shown that the disease can affect infants and has
a high incidence in other parts of the world, such as Africa (2, 3).
The incidence of typhoid fever ranges from 104 per 100,000 per-
sons per year to 273 per 100,000 persons per year (4, 5).
Currently, two vaccines are licensed for typhoid fever, the live
attenuated Ty21a vaccine and the Vi capsular polysaccharide vac-
cine. The World Health Organization (WHO) recommends the
use of typhoid vaccines in areas where the disease is endemic and
in high-risk populations (travelers, microbiology laboratory tech-
nologists, etc.) (6).
The Vi capsular polysaccharide typhoid vaccine contains
25 g of purified Vi capsular polysaccharide, to be administered
intramuscularly. It can be administered to nonpregnant individ-
uals 2 years old and older (see http://public.gsk.co.uk/products
/Typherix.html). Large-scale Vi capsular polysaccharide vaccine
efficacy studies conducted in South Africa and Nepal established
the efficacy and immunogenicity of the vaccine (7, 8). The im-
mune response to the Vi capsular polysaccharide vaccine is elic-
ited by the production of IgG antibodies and is T cell independent.
IgG antibody levels are used for the assessment of protection
against typhoid fever, as there are no directmeasures of protection
for Vi-based vaccines. IgG antibodies are elicited in 85 to 95% of
the vaccinees after Vi capsular polysaccharide vaccine administra-
tion (9). Protective levels of antibodies are elicited after 7 days and
peak at 28 days postvaccination. The antibody levels toVi capsular
polysaccharide vaccines wane with the passage of time, usually
after 2 years (10–12). Revaccination every 3 years, therefore, is
recommended for sustained protection against typhoid fever in
settings where typhoid is endemic and in high-risk populations
(13).
The correlation ofVi IgG antibody levels withVi capsular poly-
saccharide vaccine protection as well as the long-term persistence
of Vi IgG antibodies was documented in a study fromSouthAfrica
(8). The results, however, have not been widely accepted as corre-
lates of protection. Additionally, there is currently limited infor-
mation on the immune response in young children to Vi capsular
polysaccharide vaccine, in view of the immaturity of the immune
response in young children from polysaccharide vaccine admin-
istration (14).
The Disease of Most Impoverished Program of the Interna-
tional Vaccine Institute conducted Vi capsular polysaccharide
vaccine effectiveness trails in Karachi, Pakistan, targeting children
2 to 16 years old, and in Kolkata, India, targeting all those who are
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2 years old or older to assess the feasibility of introducing Vi cap-
sular polysaccharide vaccine as a regular public health program as
described in earlier publications (15, 16).We present the results of
the immune responses to Vi capsular polysaccharide vaccine in
children 2 to 16 years old from these trials.
MATERIALS AND METHODS
Study setting and population. Cluster randomized trials to assess the
effectiveness of the Vi capsular polysaccharide vaccination were con-
ducted between 2002 and 2007 in the urban slums of Karachi, Pakistan,
and Kolkata, India (15–17). The Vi capsular polysaccharide vaccine or a
control hepatitis A vaccine was administered to the target population. A
computer-generated random subsample at each site was selected for the
study of immune responses. In Kolkata, two individuals per cluster were
selected, stratified by age group (two from the age group of 2 to 18 years
and two from the group older than 18 years). In Karachi, four subjects per
cluster were selected (two from the age group of 2 to 5 years and two
from 5 to 16 years).We pooled the data from the two sites for this analysis
and hence did not use the information for children older than 16 years
from Kolkata.
Vaccines. The vaccines (Typherix and Havrix) were supplied by
GlaxoSmithKline Biologicals (GSK) (Rixensart, Belgium). Typherix was
supplied as a 0.5-ml dose of vaccine containing 25 g of the Vi capsular
polysaccharide of Salmonella typhi in a clear isotonic colorless solution. A
single dose of 0.5 ml is recommended for intramuscular injection in both
adults and children 2 years old and older. A Havrix pediatric dose was
supplied as a 0.5-ml dose consisting of 720 enzyme-linked immunosor-
bent assay (ELISA) units (ELU) of viral antigen adsorbed on 0.25 mg of
aluminum as aluminum hydroxide. Havrix was supplied as a sterile sus-
pension for intramuscular administration.
Data collection.Vaccination cards with householdmember informa-
tion were distributed prior to vaccination. The names of the children
randomly selected for blood sampling were highlighted in the vaccination
record books to ease identification when children visited vaccination cen-
ters. The study staff explained to the parent/guardian the purpose of the
blood sampling, and after written informed consent was obtained, 5ml of
blood was collected before vaccination at the vaccination post. The same
subjects were followed up at the participants’ homes at 6weeks and 2 years
after vaccination for the subsequent sampling. At the field sites, the sam-
ples were allowed to clot at room temperature for 30min to 2 h. At the end
of the day, the blood samples were transported to the clinical laboratories
of Aga Khan University Hospital (AKUH) in Karachi, Pakistan, and the
National Institute of Cholera and Enteric Diseases (NICED) in Kolkata,
India. The blood samples were centrifuged at 3,000 rpm for 15 min and
the sera were separated aseptically into multiple aliquots within 24 h after
the sampling. Sera were then stored at 80°C. Each blood sample and
aliquot was labeled with premarked stickers. Quantitative serum Vi and
hepatitis A antibody (IgG) concentrations were measured through an
ELISA technique using theGSKELISA standard (18–21). The serum anal-
yses were performed at the end of the trials, and the technicians perform-
ing assays were blinded to the vaccine codes.
Data analysis. The serological responses to the Vi capsular polysac-
charide vaccine were expressed as the geometric mean concentration
(GMC) of serum Vi IgG in ELU/ml. Descriptive statistics included calcu-
lation of percentiles and 95% confidence limits. The number of subjects
who attained protective antigen levels (concentration,150ELU/ml) and
the numberwho achieved a4-fold rise in antibody levels were compared
between intervention and control groups at baseline and at each fol-
low-up using generalized estimating equationswith the logit link function
(22). Data were analyzed using SAS version 9.3.
The studies were approved by the Institutional Review Board (IRB) of
the International Vaccine Institute, the Ethical Review Committee of the
Aga Khan University (Karachi, Pakistan), the IRBs of the National Insti-
tute of Cholera and Enteric Diseases (Kolkata, India), and the Indian
Council of Medical Research (Delhi, India).
RESULTS
Blood samples for 300 participants were collected at the time of
vaccination, 243 (81%) 6 weeks after vaccination, and 139 (46%)
at 2 years following vaccination. Sixty (39%) children in the Vi
vaccine group and 52 (35%) in the control hepatitis A vaccine
group were younger than 5 years of age. At least three blood sam-
ples were collected for 69 (45%) children in the Vi vaccine group
and 64 (44%) in the hepatitis A vaccine group (Table 1). Therewas
no statistically significant difference in the number of children
enrolled in the two groups. Twelve children in the Vi vaccine
group and 10 in the hepatitis A vaccine group had prior protective
antibody levels. The baseline Vi IgG antibody GMC levels for the
two groups were not statistically different. The baseline Vi IgG
GMC was 81.8 ELU/ml (95% confidence limits [CL], 77.2 to 86.7
ELU/ml) in the hepatitis A vaccine group and was 83.2 ELU/ml
(95% CL, 78.4 to 88.4 ELU/ml) in the Vi vaccine group (Table 2).
The Vi IgGGMCat 6weeks after vaccination for the Vi vaccine
group was 1,428.3 ELU/ml (95% CL, 1,130.0 to 1805.4 ELU/ml)
compared to 85.9 ELU/ml (95% CL, 78.0 to 94.6 ELU/ml) in the
hepatitis A vaccine group. Two years after vaccination, the Vi IgG
GMC in theVi vaccine groupwas 262.6 ELU/ml (95%CL, 190.0 to
TABLE 1 The distribution of sample size by site and age group for assessment of immune response as part of Vi capsular polysaccharide vaccine
effectiveness trials in Karachi and Kolkata
Blood sample collection
no. and time period
Age group
(yr)
Sample sizes (n [%]) in:
Total (n [%])Karachi Kolkata
Vi HepAa Total Vi HepA Total Vi HepA Total
1, day 0/prevaccination 2–5 57 (46.7) 47 (40.9) 104 (43.9) 3 (9.7) 5 (15.6) 8 (12.7) 60 (39.2) 52 (35.4) 112 (37.3)
5–16 65 (53.3) 68 (59.1) 133 (56.1) 28 (90.3) 27 (84.4) 55 (87.3) 93 (60.8) 95 (64.6) 188 (62.7)
2, 6 wk after vaccination 2–5 40 (43.5) 36 (39.6) 76 (41.5) 2 (6.5) 3 (10.3) 5 (8.3) 42 (34.2) 39 (32.5) 81 (33.3)
5–16 52 (56.5) 55 (60.4) 107 (58.5) 29 (93.6) 26 (89.7) 55 (91.7) 81 (65.9) 81 (67.5) 162 (66.7)
3, 2 yr after vaccination 2–5 20 (43.5) 17 (37.8) 37 (40.7) 1 (4.0) 2 (8.7) 3 (6.3) 21 (29.6) 19 (27.9) 40 (28.8)
5–16 26 (56.5) 28 (62.2) 54 (59.3) 24 (96.0) 21 (91.3) 45 (93.8) 50 (70.4) 49 (72.1) 99 (71.2)
All three samples 2–5 19 (42.2) 14 (34.2) 33 (38.4) 1 (4.2) 2 (8.7) 3 (6.4) 20 (29.0) 16 (25.0) 36 (27.1)
5–16 26 (57.8) 27 (65.9) 53 (61.6) 23 (95.8) 21 (91.3) 44 (93.6) 49 (71.0) 48 (75.0) 97 (72.9)
a HepA, hepatitis A vaccine.
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362.8 ELU/ml) compared to 90.4 ELU/ml (95% CL, 79.1 to 103.4
ELU/ml) in the hepatitis A vaccine group. Within the groups vac-
cinated with Vi capsular polysaccharide vaccine, the Vi IgG GMC
reduced to 262.6 ELU/ml compared to 1,428.3 ELU/ml at 6 weeks
after vaccination (Table 2).
The proportion of childrenmaintaining a protective level of Vi
IgG antibodies 2 years after vaccination in the Vi vaccine group
was statistically significantly different from the proportion in the
control hepatitis A vaccine group (39.1% in Vi vaccine group and
6.1% in hepatitis A vaccine group; P 0.001) (Fig. 1). Six children
(4.9%) in the sample did not develop Vi IgG antibodies after re-
ceiving the Vi capsular polysaccharide vaccine. All nonresponders
TABLE 2 Comparison of immune response to the Vi capsular polysaccharide vaccine and the control hepatitis A vaccine in children between the
ages of 2 and 16 years in Karachi and Kolkata
Variables
Values for children receiving the indicated vaccine
PVi Hepatitis A
Overall (age 2–16 yr)
Blood sample 1, day 0 (prevaccination)a
No. 153 147
GMCb (95% confidence limits) 83.2 (78.4–88.4) 81.8 (77.2–86.7) 0.692
Attained protective antigen level (n [%])c 12 (7.8) 10 (6.8) 0.723
Blood sample 2, 6 wk since vaccination
No. 123 120
GMC (95% confidence limits) (ELU/ml) 1,428.3 (1130–1805.4) 85.9 (78–94.6) 0.001
Attained protective antigen level (n [%]) 117 (95.1) 9 (7.5) 0.001
Achieved a4-fold rised (n [%]) 104 (86.7) 2 (1.7) 0.001
Blood sample 3, 2 yr since vaccination
No. 71 68
GMC (95% confidence limits) (ELU/ml) 262.6 (190–362.8) 90.4 (79.1–103.4) 0.001
Attained protective antigen level (n [%]) 40 (56.3) 8 (11.8) 0.001
Achieved a4-fold rise (n [%]) 27 (39.1) 4 (6.1) 0.001
Age5 yr
Blood sample 1, day 0 (prevaccination)
No. 60 52
GMC (95% confidence limits) (ELU/ml) 75 (75–75) 76.2 (73.8–78.7) 0.304
Attained protective antigen level (n [%]) 0 (0.0) 1 (1.9) e
Blood sample 2, 6 wk since vaccination
No. 42 39
GMC (95% confidence limits) (ELU/ml) 832.2 (546–1268.5) 82.7 (67.8–100.8) 0.001
Attained protective antigen level (n [%]) 36 (85.7) 1 (2.6) 0.001
Achieved a4-fold rise (n [%]) 29 (70.7) 1 (2.7) 0.001
Blood sample 3, 2 yr since vaccination
No. 21 19
GMC (95% confidence limits) (ELU/ml) 133.4 (93.7–190) 96.5 (67–139) 0.218
Attained protective antigen level (n [%]) 8 (38.1) 2 (10.5) 0.071
Achieved a4-fold rise (n [%]) 5 (25.0) 2 (11.1) 0.379
Age 5–15.9 yr
Blood sample 1, day 0 (prevaccination)
No. 93 95
GMC (95% confidence limits) (ELU/ml) 89 (80.8–98.1) 85.1 (77.9–92.9) 0.497
Attained protective antigen level (n [%]) 12 (12.9) 9 (9.5) 0.463
Blood sample 2, 6 wk since vaccination
No. 81 81
GMC (95% confidence limits) (ELU/ml) 1,890 (1447.3–2468.1) 87.5 (78.5–97.6) 0.001
Attained protective antigen level (n [%]) 81 (100.0) 8 (9.9) e
Achieved a4-fold rise (n [%]) 75 (94.9) 1 (1.3) 0.001
Blood sample 3, 2 yr since vaccination
No. 50 49
GMC (95% confidence limits) (ELU/ml) 348.9 (230.2–528.8) 88.2 (77.3–100.5) 0.001
Attained protective antigen level (n [%]) 32 (64.0) 6 (12.2) 0.001
Achieved a4-fold rise (n [%]) 22 (44.9) 2 (4.2) 0.001
a Blood sample 1 is from day 0 (prevaccination), 2 is from week 6 since vaccination, and 3 is from year 2 since vaccination.
b GMC, geometric mean concentration. All values are expressed in ELU/ml.
c Attained protective antigen level (Vi,150 ELU/ml [GSK in-house standard]). We used the value 75 ELU/ml (midpoint) for those listed as150 ELU/ml in the report.
d Achieved a4-fold rise in antibodies, in relation to baseline, as detected in the cited blood sample.
e P value is not possible due to 0 in one of the cells.
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were5 years old. The Vi IgG antibody levels dropped below the
protective level in 31 (43.7%) children after 2 years. The immune
response to the Vi capsular polysaccharide vaccine in younger
children (5 years old) was not statistically different compared to
the response in older children (5 to 16 years old) at 6 weeks and 2
years after vaccination (Table 2).
DISCUSSION
Typhoid fever incidence continues to be high in children, and in
the absence of long-term interventions (such as improvements in
water quality and sanitation), vaccination is an alternative short-
term strategy. InKolkata andKarachi, areas of high endemicity for
typhoid fever, the Vi capsular polysaccharide vaccine is immuno-
genic in children aged 2 to 16 years, with a considerable propor-
tion of the vaccinees retaining a protective level of antibodies after
2 years. However, immune responses are higher in older children
(5 to 16 years old) than in younger children (2 to5 years old).
Approximately 7% of children enrolled in our study had pro-
tective levels of Vi IgG antibodies prior to vaccination, suggesting
a high prevalence of immune response due to natural infection.
Natural infection with S. typhi does not confer long-term immu-
nity (23, 24). The mechanism through which a polysaccharide
vaccine may interact and boost the existing immunity due to nat-
ural infection is not well understood. However, children who had
prior antibodies responded better to the Vi vaccine (data not
shown).
It is important to note that the correlates of protection for
typhoid fever vaccines are not established. The ELISAmethod has
been the most common way to assess immunogenicity (8, 25, 26);
however, the lack of standardized quantitative IgG reference sera
makes direct comparison of immunogenicity data from different
studies impossible. In our study, the Vi IgG antibody levels were
measured using the ELISA method with the GSK Biologicals’ ref-
erence standard, for which the threshold had been standardized
for their internal use (18–21). Therefore, we were unable to com-
pare our results with those of other studies of Vi immune re-
sponses due to differences in measurement methods and scales.
Nonetheless, the results from our study complement the effec-
tiveness studies and support the importance of typhoid vaccina-
tion as a preventive measure for typhoid control in areas where
typhoid is highly endemic. However, these results also pose a pro-
grammatic challenge due to the short durations of the presence of
Vi IgG in the vaccinated population as well as of the immune
responses in children5 years old, due to the polysaccharide vac-
cine’s T cell independent immunity and the immaturity of the
immune response in younger children (27).
Evenwith a shorter duration of the presence of Vi IgG antibod-
ies in younger children, the effectiveness study in Kolkata had
shown a significant clinical protection in younger children when
the vaccine was provided to the whole community (16). This
larger vaccination coveragemay have contributed to the interrup-
tion in disease transmission in the community, inducing indirect
protection to the younger children. Similarly, a study of the long-
term persistence of Vi IgG antibodies in South Africa supports the
argument for the use of a series of vaccination campaigns in high-
risk areas where, over a 10-year period, the majority of the popu-
lation will be protected with Vi capsular polysaccharide vaccina-
tion (28).
In regions of the world with high endemicity, typhoid fever
incidences are higher in children5 years old compared to those
in older children. The immune response elicited by natural infec-
tion as well as by the vaccine in the children younger than 5 years
FIG 1 Comparison of anti-Vi antibody levels at three different time points by age group and their corresponding 95% confidence intervals from the studies of
immune response to Vi capsular polysaccharide vaccine in Karachi and Kolkata. HepA, hepatitis A vaccine.
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needs further exploration. In the absence of an effective vaccine
for younger children, other methods of prevention at the house-
hold level, such as hand washing and drinking clean water, should
be adopted to prevent typhoid fever in children5 years old (29,
30). Further, after much-awaited development and introduction,
the Vi conjugate vaccine is likely to overcome the limitations of
the Vi capsular polysaccharide vaccine, as the conjugate vaccine
was shown to be more immunogenic in younger children and to
confer sustained protection (31, 32).
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